UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Inva

UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Inva#UroGen #Announces #Updated #18Month #Duration #Response #DOR #Phase #ENVISION #Trial #UGN102 #Investigational #Treatment #Recurrent #LowGrade #IntermediateRisk #NonMuscle #Inva